Published June 2023 | Version Published + Supplemental Material
Journal Article Open

Genetic Deletion of the LINC00520 Homolog in Mouse Aggravates Angiotensin II-Induced Hypertension

  • 1. ROR icon Taichung Veterans General Hospital
  • 2. ROR icon National Chiao Tung University
  • 3. ROR icon California Institute of Technology
  • 4. ROR icon University of California, San Diego
  • 5. ROR icon University of Utah
  • 6. ROR icon VA Salt Lake City Healthcare System
  • 7. ROR icon City Of Hope National Medical Center

Abstract

(1) Background: Hypertension is a complex, multifactorial disease that is caused by genetic and environmental factors. Apart from genetic predisposition, the mechanisms involved in this disease have yet to be fully understood. We previously reported that LEENE (lncRNA enhancing endothelial nitric oxide expression, transcribed from LINC00520 in the human genome) regulates endothelial cell (EC) function by promoting the expression of endothelial nitric oxide synthase (eNOS) and vascular growth factor receptor 2 (VEGFR2). Mice with genetic deletion of the LEENE/LINC00520 homologous region exhibited impaired angiogenesis and tissue regeneration in a diabetic hindlimb ischemia model. However, the role of LEENE in blood pressure regulation is unknown. (2) Methods: We subjected mice with genetic ablation of leene and wild-type littermates to Angiotensin II (AngII) and monitored their blood pressure and examined their hearts and kidneys. We used RNA-sequencing to identify potential leene-regulated molecular pathways in ECs that contributed to the observed phenotype. We further performed in vitro experiments with murine and human ECs and ex vivo experiments with murine aortic rings to validate the select mechanism. (3) Results: We identified an exacerbated hypertensive phenotype of leene-KO mice in the AngII model, evidenced by higher systolic and diastolic blood pressure. At the organ level, we observed aggravated hypertrophy and fibrosis in the heart and kidney. Moreover, the overexpression of human LEENE RNA, in part, restored the signaling pathways impaired by leene deletion in murine ECs. Additionally, Axitinib, a tyrosine kinase inhibitor that selectively inhibits VEGFR suppresses LEENE in human ECs. (4) Conclusions: Our study suggests LEENE as a potential regulator in blood pressure control, possibly through its function in ECs.

Additional Information

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). (This article belongs to the Special Issue Women's Special Issue Series: Noncoding RNAs and Diseases) The authors wish to thank Yin Wang at the Department of Diabetes and Cancer Metabolism of the City of Hope, Szu-Ling Chang at Tai-Chung Veteran General Hospital, and Cheng-Hsueh Wu at Taipei General Hospital for their technical assistance with the study. Research reported in this publication included work performed in the Integrative Genomics and Pathology Cores supported by the National Cancer Institute of the National Institutes of Health under grant number P30CA033572. This study was funded in part by grants from the National Institutes of Health (R01 HL145170 to Z.B.C., R01 DK065073 and R01 HL106089 to R.N. and Z.B.C., R01GM141096 to Z.B.C., and K08HL148540 to J.W.R., a predoctoral fellowship from California Institute of Regenerative Medicine EDU4-12772 to A.T., and a postdoctoral fellowship from the American Heart Association 903829 to G.Z. Research reported in this publication included work performed in the Integrative Genomics, Light Microscopy and Digital Imaging, and Pathology Cores supported by the National Cancer Institute of the NIH under award number P30CA033572. Author Contributions: Z.B.C., X.T. and C.-H.L. conceived and designed the study. X.T. and C.-H.L. performed the in vivo, in vitro, and ex vivo experiments. N.K.M. and R.C. (Rahuljeet Chadha) performed the imaging analysis. D.Y., X.L. and A.T. performed in vitro experiments. Y.L. generated the RNA-seq libraries. R.C. (Riccardo Calandrelli), X.T. and Y.L. performed the subsequent analysis. G.Z. performed cardiac function assessment, and Z.V.W. supervised these experiments. M.A. performed the kidney analysis. S.Z., R.N., Y.-T.S., J.-W.R. and Z.B.C. provided critical discussion. S.Z., R.N., Y.-T.S. and Z.B.C. obtained funding for this study. X.T. drafted the manuscript. Y.L., N.K.M., Z.V.W., J.-W.R., R.N., M.A., Y.-T.S. and Z.B.C. edited the manuscript. Z.B.C. supervised the study. All authors have read and agreed to the published version of the manuscript. Institutional Review Board Statement: All animal experiments conducted have been approved by the Institute Animal Care and Use Committees at the City of Hope. Informed Consent Statement: Not applicable. Data Availability Statement: RNA-seq data from lung EC are available at GEO with accession No. GSE226638. Conflicts of Interest. J.W.R. received industry-sponsored research grant from Pfizer on an unrelated work. S.Z. is a founder and board member of Genemo Inc, San Diego, CA, USA.

Attached Files

Published - ncrna-09-00031-v2.pdf

Supplemental Material - ncrna-09-00031-s001.zip

Files

ncrna-09-00031-s001.zip

Files (3.8 MB)

Name Size
md5:973fcce1bedce7dc2dd8232e25b7faaf
787.5 kB Preview Download
md5:78fe6935287da674da2f63f18663106e
3.1 MB Preview Download

Additional details

Identifiers

PMCID
PMC10204496
Eprint ID
122178
Resolver ID
CaltechAUTHORS:20230707-401491600.4

Funding

NIH
P30CA033572
NIH
R01 HL145170
NIH
R01 DK065073
NIH
R01 HL106089
NIH
R01GM141096
NIH
K08HL148540
California Institute for Regenerative Medicine (CIRM)
EDU4-12772
American Heart Association
903829

Dates

Created
2023-07-17
Created from EPrint's datestamp field
Updated
2023-07-17
Created from EPrint's last_modified field